Overuse of opioids for acute migraine in an Australian emergency department

Author(s):  
Emily Joules ◽  
Michael Yeoh
Pain Practice ◽  
2014 ◽  
Vol 15 (8) ◽  
pp. 701-705 ◽  
Author(s):  
Hossein Moshtaghion ◽  
Najmeh Heiranizadeh ◽  
Abolghasem Rahimdel ◽  
Alireza Esmaeili ◽  
Hamidreza Hashemian ◽  
...  

2021 ◽  

Background: Treatment provided in an emergency department is aimed at alleviating pain immediately with minimized adverse effects as well as warding off further migraine attacks. The primary aim of this article is to compare the effectiveness of oral paracetamol versus zolmitriptan in treating acute migraine attacks. Methods: This prospective, randomized, and controlled study was carried out at a tertiary care hospital visited by 95,000 patients annually. The study recruited 200 participants who were randomized into two groups. One group received 1000 mg paracetamol while the other group received 2.5 mg zolmitriptan orally. Baseline pain scores were recorded using the Visual Analogue Scale (VAS) and Numeric Rating Scale (NRS) at 15, 30 and at 60 min following administration of the study drugs. Patients requiring further treatment were provided fentanyl at a dosage of 1 µg/kg as a rescue therapy. Results: A significant decrease was evident in VAS and NRS scores following the administration of the study drugs in both groups (P < 0.001). The change in VAS pain scores after 15, 30 and 60 min was calculated as 17.0 ± 13.9, 41.2 ± 16.3 and 61.2 ± 17.5 mm, respectively, in the paracetamol group and 14.2 ± 11.7, 39.2 ± 17.9 and 59.2± 19.3 mm, respectively, in the zolmitriptan group, which did not indicate significant differences (P = 0.103, P = 0.425, P = 0.483, respectively). Likewise, NRS pain scores showed a downward trend in line with VAS pain scores and did not yield a significant difference (P = 0.422). No significant difference concerning rescue therapy was noted between the two groups (P = 0.596). Conclusion: Oral paracetamol and zolmitriptan prove to be similarly effective and have low incidence of acute side effects in treating acute migraine cases without aura.


Cephalalgia ◽  
1991 ◽  
Vol 11 (5) ◽  
pp. 207-213 ◽  
Author(s):  
Bruce MT Rowat ◽  
Charles F Merrill ◽  
Alan Davis ◽  
Valerie South

Three hundred and ninety-seven patients who presented to the emergency department were screened for a randomized, double-blind, placebo-controlled study of iv granisetron (40 μg/kg or 80 μg/kg) in acute migraine. Twenty-eight patients fulfilled the stringent eligibility criteria and completed the study. Rescue medication was required 2 h post-infusion in 8 of 10 patients receiving granisetron 40 μg/kg, 5 of 10 patients receiving granisetron 80 μg/kg, and 6 of 8 patients receiving placebo. Significant improvement (p < 0.05) in headache pain (on a visual analogue scale and categorical scale) was observed in the 80–μg/kg group. Headache pain evaluated with the Hunter headache scale indicated improvement for the sensory and affective components of headache pain in both granisetron groups. Except for more nausea at 30 min in the placebo group, no significant differences were noted between treatments. All three treatments were well tolerated. Granisetron may be effective for acute migraine headache; however, further studies with increased patient numbers are required.


Neurology ◽  
2007 ◽  
Vol 69 (22) ◽  
pp. 2038-2044 ◽  
Author(s):  
B. W. Friedman ◽  
P. Greenwald ◽  
T. C. Bania ◽  
D. Esses ◽  
M. Hochberg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document